TABLE OF REGULATORY SECTIONS AND RESPONDENT BURDEN—Continued

Type of burden	Transactions per year	Estimated time per transaction	Annual response burden (hours)
Total Annual Burden			142,058

[1] No new HEAL loans.
[2] Burden is from Subpart E—School.

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14–36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: June 3, 1997.

James J. Corrigan,

Acting Associate Administrator for Management and Program Support.

[FR Doc. 97–15278 Filed 6–10–97; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Methods for Detecting Cervical Cancer

T Ried et al. (NHGRI)
U.S. Patent Serial No. 08/781,424 filed 10 Jan 97
Licensing Contact: Mary Savagner, 301/496–7735 ext. 205

Last year, nearly 16,000 women in the United States were diagnosed with invasive cervical carcinoma and nearly 5,000 women died from the disease. While the widespread promotion and use of the Pap smear has contributed to the reduced mortality rate associated with the disease over the last 30 years, there is still a need for improvement and optimization of the screening process. Despite tremendous efforts, the automated analysis of cervical PAP smears based on cytopathological stains has not been achieved. Also, cytopathological analyses reveal insufficient information to predict disease progression.

This invention provides a method of detecting the presence of invasive cervical carcinoma by detecting in a cervical cell taken from a patient the presence of a chromosomal aberration indicating the presence of invasive cervical carcinoma. The invention also provides a method of diagnosing advanced-stage cervical carcinoma in a patient as well as a method of classifying the progression of dysplastic cervical cells from non-invasive to invasive cervical carcinoma. In addition, the invention provides kits comprising nucleic acids that specifically hybridize in chromosome 3q and specifically hybridize to another chromosome, and to compositions comprising nucleic acids. (portfolio: Cancer—Diagnostics, in vitro, other)

Chimeric Nucleic Acid Sequences Encoding attenuated Hepatitis A Viruses and the Use of These Sequences and Viruses as Vaccines

SU Emerson, SA Harmon, E Ehrenfeld, DF Summers (NIAID)
Serial No. 08/547,482 filed 24 Oct 95
Licensing Contact: Gloria Richmond, 301/496–7056 ext. 268

This invention is directed to chimeric hepatitis A viruses, containing mutations in the 2A gene, which will be used as the basis for an attenuated vaccine for humans. The mutations in the 2A gene are unusual because they are not naturally occurring mutations but were engineered into an infectious cDNA clone. These mutations in 2A are able to decrease pathology substantially and offer the opportunity of constructing a virus that will induce effective immunity without causing disease. Sales of the inactivated vaccine in Europe have demonstrated the commercial importance of a vaccine for hepatitis A. An attenuated vaccine would be more economical and easier to administer. (portfolio: Infectious Diseases—Vaccines, viral, non-AIDS)

Vaccine for Dengue Virus

C–J Lai, M Bray, AG Pletnev, R Men, Y–M Zhang, KH Eckels (NIAID)
Serial No. 08/250,802 filed 27 May 94
Licensing Contact: Gloria H. Richmond, 301/496–7056 ext 268

The claimed invention relates to recombinant modified or viable chimeric dengue viruses for use as vaccines against dengue and other flavivirus disease, including tick-borne encephalitis. Dengue is a mosquito-transmitted viral disease which occurs in tropical and subtropical regions throughout the world. Inactivated whole dengue virus vaccines have been shown to be insufficiently immunogenic and live dengue virus vaccines prepared by serial passage in cell culture have not been shown to be consistently attenuated. A dengue vaccine is still not available. The present invention represents a technical breakthrough, which provides new approaches to dengue vaccines by construction of chimeric dengue viruses of all four serotypes and strategic modification to produce attentuated virus strains. Several fields of use remain available for licensing. (portfolio: Infectious Diseases—Vaccines, viral, non-AIDS)

Parvovirus B19 Receptor and Parvovirus B19 Detection

N Young, K Brown (NHLBI)
Serial No. 08/034,132 filed 22 Mar 93; U.S. Patent 5,449,608 issued 12 Sep 95
Licensing Contact: Gloria H. Richmond, 301/496–7056 ext 268

The claimed invention provides a method of detecting the presence of a parvovirus in a sample. Parvoviruses infect animals and man. In man, the only known pathogenic member of this family is parvovirus B19. The inventors have identified the parvovirus B19 receptor which provides for a method to diagnose, prevent, and treat parvovirus infection utilizing the binding affinity for the receptor. (portfolio: Infectious

Diseases—diagnostics, viral, non-AIDS; Infectious Diseases—Therapeutics, anti-viral, non-AIDS)

Dated: May 30, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97–15299 Filed 6–10–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Chemistry and Related Sciences.

Date: June 24, 1997.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 5150, Telephone Conference.

Contact Person: Dr. Zakir Bengali, Scientific Review Administrator, 6701 Rockledge Drive, Room 5150, Bethesda, Maryland 20892, (301) 435–1742.

Name of SEP: Behavioral and Neurosciences.

Date: July 2, 1997.

Time: 8:30 a.m.

Place: Capitol Holiday Inn, Washington, DC.

Contact Person: Dr. Jane Hu, Scientific Review Administrator, 6701 Rockledge Drive, Room 5168, Bethesda, Maryland 20892, (301) 435–1245.

Name of SEP: Biological and Physiological Sciences.

Date: July 7, 1997.

Time: 11:30 a.m.

Place: NIH, Rockledge 2, Room 4132, Telephone Conference.

Contact Person: Dr. Syed Quadri, Scientific Review Administrator, 6701 Rockledge Drive, Room 4132, Bethesda, Maryland 20892, (301) 435–1211.

Name of SEP: Biological and Physiological Sciences.

Date: July 7, 1997.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4132, Telephone Conference.

Contact Person: Dr. Syed Quadri, Scientific Review Administrator, 6701 Rockledge Drive, Room 4132, Bethesda, Maryland 20892, (301) 435–1211.

Name of SEP: Biological and Physiological Sciences.

Date: July 11, 1997.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Michael Micklin, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435–1258.

Name of SEP: Behavioral and Neurosciences.

Date: July 16, 1997.

Time: 8:30 a.m.

Place: Ramada Inn, Rockville, MD.

Contact Person: Dr. Luigi Giacometti, Scientific Review Administrator, 6701 Rockledge Drive, Room 5170, Bethesda, Maryland 20892, (301) 435–1246.

Name of SEP: Chemistry and Related Sciences.

Date: July 17, 1997.

Time: 8:30 a.m.

Place: Holiday Inn-Georgetown, Washington, DC.

Contact Person: Dr. John Bowers, Scientific Review Administrator, 6701 Rockledge Drive, Room 4168, Bethesda, Maryland 20892, (301) 435–1725.

Name of SEP: Biological and Physiological Sciences.

Date: July 17, 1997.

Time: 2:45 p.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Martin Padarathsingh, Scientific Review Administrator, 6701 Rockledge Drive, Room 4146, Bethesda, Maryland 20892, (301) 435–1717.

Name of SEP: Biological and Physiological Sciences.

Date: July 17–18. 1997.

Time: 8:20 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Bob Weller, Scientific Review Administrator, 6701 Rockledge Drive, Room 5204, Bethesda, Maryland 20892, (301) 435–1259.

Name of SEP: Biological and Physiological Sciences.

Date: July 25, 1997.

Time: 1:00 p.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Michael Micklin, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435–1258.

Name of SEP: Chemistry and Related Sciences.

Date: July 30–31, 1997.

Time: 8:30 p.m.

Place: Hyatt Regency, Bethesda, MD.

Contact Person: Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 5218, Bethesda, Maryland 20892, (301) 435–1180.

Name of SEP: Behavioral and Neurosciences.

Date: August 6, 1997.

Time: 8:30 a.m.

Place: Hyatt Regency Hotel, Bethesda, MD.

Contact Person: Dr. Carl Banner, Scientific Review Administrator, 6701 Rockledge Drive, Room 5182, Bethesda, Maryland 20892, (301) 435–1251.

Purpose/Agenda: To review Small Business Innovation Research.

Name of SEP: Biological and Physiological Sciences.

Date: June 27, 1997.

Time: 2:00 p.m.

Place: Latham Hotel, Washington, DC.

Contact Person: Dr. Cheryl Corsaro, Scientific Review Administrator, 6701 Rockledge Drive, Room 6172, Bethesda, Maryland 20892, (301) 435–1045.

Name of SEP: Biological and Physiological Sciences.

Date: July 14–15, 1997.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Syed Quadri, Scientific Review Administrator, 6701 Rockledge Drive, Room 4132, Bethesda, Maryland 20892, (301) 435–1211.

Name of SEP: Biological and Physiological Sciences.

Date: July 16, 1997.

Time: 8:30 a.m.

Place: Holiday Inn, Silver Spring, MD.

Contact Person: Dr. Bob Weller, Scientific Review Administrator, 6701 Rockledge Drive, Room 5204, Bethesda, Maryland 20892, (301) 435–1259.

Name of SEP: Biological and Physiological Sciences.

Date: July 25, 1997.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Michael Micklin, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435–1258.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Date: June 5, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–15296 Filed 6–10–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Record Linkage Studies Utilizing Resources in Population-Based Tumor Registries.

Date: June 10, 1997.